Brief: Appili Therapeutics Reports New Late-Stage Clinical Program ATI-1801 To Treat Cutaneous Leishmaniasis
13/04/2022 12:47
April 13 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS ANNOUNCES NEW LATE-STAGE CLINICAL
PROGRAM
ATI-1801 TO TREAT CUTANEOUS LEISHMANIASIS
* APPILI THERAPEUTICS - TOPICAL FORMULATION OF PAROMOMYCIN
ATI-1801 ALREADY SHOWN TO BE SAFE AND EFFECTIVE AGAINST
DISFIGURING DISEASE IN PHASE 3 STUDY
Source text for Eikon: ID:nBw6yg6sRa
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez